Last update June 10, 2018

Naftifine Hydrochloride

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A synthetic broad-spectrum antifungal agent used to treat dermatophyte fungi applied topically on the skin.
Authorized in children over 2 years old (FDA 2017).

Since the last update we have not found published data on its excretion in breastmilk.

Cutaneous absorption to the patient’s blood is extremely low: 2.5 - 6% (FDA 2014, Gupta 2008, Leachman 2006), which makes transfer to breastmilk in significant amounts very unlikely.

It is advisable to avoid application of creams, gels and other topical products containing paraffin (mineral oil) on the nipple so that the infant does not absorb them (Concin 2008, Noti 2003).

Alternatives

We do not have alternatives for Naftifine Hydrochloride since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Naftifine Hydrochloride is also known as


Naftifine Hydrochloride in other languages or writings:

Group

Naftifine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Naftifine Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Derm: 4 - 6 %
Molecular weight 287 daltons
T½ 48 - 72 hours

References

  1. FDA. Naftifine. Drug Summary. 2017 Full text (in our servers)
  2. FDA. Naftifine (Naftin) Drug Summary. 2014 Full text (in our servers)
  3. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  4. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008 Abstract
  5. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006 Abstract
  6. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract

Total visits

7,966

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM